seek and you will find
- …
seek and you will find
- …
SeekInCure®
The first-in-class blood-based pan-cancer recurrence monitoring test
SeekInCure® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .
A panoramic view of cancer genomic landscape
cfDNA detection via NGS drawing the view of cancer genomic landscape
Cutting-edge multivariate algorithm
Genomics combined with proteomics,capturing the signal of cancer recurrence
Multidimensional fingerprint
CNA, Fragmentation and protein markers discovering the early cancer recurrence
Big date and Artificial intelligence
CRI model based on machine learning evaluating the risk of cancer recurrence precisely
Specifications
◉ Indicated subjects: post-surgery cancer patients
◉ Sample requirement: 10ml peripheral blood
◉ Result readout: CRI (cancer recurrence index)
◉ TAT: 10 working days
Sampling time:
How it works
Pre-test inquiry
Informed consent
Blood-draw
Testing
Analyzing + Interpretation
Reporting
Contact Us
10320 Camino Santa Fe, Suite G
San Diego, CA 92121
United States
info@seekincancer.com
© 2024 SeekIn Inc.
All Rights Reserved.